Kantonsspital St.Gallen
login

COSMIC 312

David Semela & Roman Stillhard

abstract

A Randomized, Controlled Phase 3 Study of Cabozantinib
(XL184) in Combination with Atezolizumab versus Sorafenib
in Subjects with Advanced Hepatocellular Carcinoma Who
Have Not Received Previous Systemic Anticancer Therapy

Randomisation 2:1:1:1
Cabozantinib + Atezolizumab
Sorafenib
Cabozantinib
   
type of project clinical studies
status completed
start of project 2019
end of project 2020
study design This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in
combination with atezolizumab versus sorafenib in subjects with advanced HCC who have not
received previous systemic anticancer therapy.
responsible person PD Dr. Dr. David Semela